Ingelise Saunders takes over as CEO of SLS Invest
This article was originally published in Scrip
Ingelise Saunders has been appointed CEO of SLS Invest to take the place of Per Carendi who is retiring after four years in the role. Ms Saunders' previous positions include CEO of ACE BioSciences and CEO of Celltech Pharmaceuticals. She is currently CEO of Action Pharma, one of SLS Invest's portfolio companies and serves on the board of Topotarget.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.